Qualigen Therapeutics

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Earnings data Q3 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL and virtually.

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the first quarter ended March 31, 2022, and provides an update on its diagnostics business, therapeutics pipeline, and other corporate developments.

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

Innovative Technology Aims to Accelerate Antimicrobial Susceptibility Test Result Times by Six-Fold

Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel

Compan ies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “ Superbugs , ” a Rising Global Health Crisis

Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex

CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division.

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

Agile Therapeutics

Histogen

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today

Actinium Pharmaceuticals

Lixte Biotech

PolarityTE Inc

Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.

Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?

Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer Research (AACR). QN-302 showed potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo metastatic.

Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers

Data Highlights In V ivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers

Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference

Company Prepared for Growth and Improved Profitability of its Diagnostics Business

Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®

CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today announces its financial results for the fiscal year ended December 31, 2021.

Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead the preclinical development of lead drug candidate QN-302. Qualigen is initially investigating QN-302 for the potential treatment of pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers.

Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302

Abstracts Review Positive In vivo Data an d the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers

Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference

CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today announces the mutual extension of a research agreement with University of Louisville Research Foundation (ULRF). The revised agreement expands the Company's collaboration with the research institution to develop its ongoing RAS-F platform currently in the discovery stage for solid tumors through Q1 of 2023.

Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program

CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation and diagnostics, today issues the following Letter to Shareholders:

Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders

Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New Orleans

Data from Qualigen Therapeutics' Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference

Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor

Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302

Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer

Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics

Meten Holding Group Ltd.

ShiftPixy

Check these three Reddit penny stocks out for your watchlist next year The post Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Reddit Penny Stocks to Buy Now? 3 You Need to Watch in 2022

Biofrontera

Inspira Technologies Oxy BHN Ltd

Petros Pharmaceuticals

Reliance Global Group

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard

Ensysce Biosciences

Farmmi

Here are three penny stocks to watch right now The post Best Penny Stocks To Buy This Week? 3 For Your Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy This Week? 3 For Your Watch List

Energy Focus

ReTo Eco-Solutions

Society Pass

X4 Pharmaceuticals Inc

Penny stocks to watch after Society Pass (NASDAQ: SOPA) skyrockets in December. The post Low Float Penny Stocks To Watch After SOPA Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Low Float Penny Stocks To Watch After SOPA Stock Explodes

Ms. Bro i drick to retain title of Chief Strategy Officer

Qualigen Therapeutics Promotes Amy Broidrick to President

CARLSBAD, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase and sale of 5,880,000 shares of common stock for $1.50 per share (i.e., for aggregate gross proceeds of $8,820,000).

Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering

iBio

Palatin Technologies

Trading biotech penny stocks right now? Check these three out The post Hot Biotech Penny Stocks to Buy Today?

Hot Biotech Penny Stocks to Buy Today? 3 For Your December Watchlist

News for Qualigen Therapeutics Stock (QLGN)